May 1996 - Volume 5 - Issue 5 - Contributor Index

Alphabetical Search
I
J
O
Q
X
Author:
Booke, Michael
Author:
Bourgeois, Marc

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Burdick, Marie
Author:
Buurman, Wim A.

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Doi, Elvira M.
Author:
Ejiofor, Joseph

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Green, Maranne

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Hinder, Frank
Author:
Hunt, Julia
Author:
Hunt, Thomas K.
Author:
Lacy, D Brooks

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Li, Ding-gang
Author:
McGuire, Roy
Author:
Meyer, Tory
Author:
Rogiers, Peter
Author:
Schmartz, Denis
Author:
Simonson, G.
Author:
Spapen, Herbert
Author:
Tiao, Greg
Author:
Ulrich, Chris

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;

Froon, Albert M.F.; Greve, Jan Willem M.; Buurman, Wim A.; More

Shock. 5(5):313-319, May 1996.

Author:
Zabel, David D.
Author:
Zhang, Haibo
Show: